HC Wainwright Brokers Reduce Earnings Estimates for Compugen

Compugen Ltd. (NASDAQ:CGEN) – Equities researchers at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Compugen in a report issued on Tuesday, May 19th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn ($0.10) per share for the quarter, down from their prior estimate of ($0.09). The consensus estimate for Compugen’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen’s Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.38) EPS and FY2027 earnings at ($0.42) EPS.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $2.18 million for the quarter, compared to analyst estimates of $1.57 million. Compugen had a return on equity of 47.72% and a net margin of 47.97%.

CGEN has been the topic of several other research reports. Truist Financial upgraded Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Lake Street Capital assumed coverage on Compugen in a research report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compugen currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Compugen Price Performance

Shares of CGEN stock opened at $2.70 on Thursday. The firm has a market capitalization of $255.29 million, a price-to-earnings ratio of 7.30 and a beta of 2.79. The business has a fifty day moving average of $2.53 and a 200 day moving average of $2.01. Compugen has a 1 year low of $1.29 and a 1 year high of $3.23.

Hedge Funds Weigh In On Compugen

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in shares of Compugen by 12.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after buying an additional 176,088 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in Compugen during the first quarter worth about $68,000. Calamos Advisors LLC purchased a new position in Compugen during the first quarter valued at approximately $63,000. Platform Technology Partners raised its position in Compugen by 10.0% during the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 5,000 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Compugen in the fourth quarter valued at approximately $104,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.